Molecular and Structural Basis of Portal Hypertension

Clinics in Liver Disease

Volumn 10, Issue 3, 2006, Pages 445-457

  Moreau, Richard ^a   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; ENDOCANNABINOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN; VASCULOTROPIN;

ANGIOGENESIS; ARTERY BLOOD FLOW; COLLATERAL CIRCULATION; ENDOTOXEMIA; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; HYPERKINESIA; LIVER CIRRHOSIS; MOLECULAR MECHANICS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PROTEIN EXPRESSION; REVIEW; SEPSIS; SMOOTH MUSCLE FIBER; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; HUMANS; HYPERTENSION, PORTAL; PORTAL VEIN;

EID: 33845386041     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.011     Document Type: Review

References (61)

1. Lebrec D., and Moreau R. Pathophysiology of portal hypertension. Hepatogastroenterology 46 (1999) 1426-1428
2. Rockey D.C. Cell and molecular mechanisms of increased intrahepatic resistance and hemodynamic correlates. In: Sanyal A.J., and Shah V.H. (Eds). Clinical gastroenterology: portal hypertension (2005), Humana Press Inc., Totowa (NJ) 37-50
3. Pinzani M., and Vizzutti F. Anatomy and vascular biology of the cells in the portal circulation. In: Sanyal A.J., and Shah V.H. (Eds). Clinical gastroenterology: portal hypertension (2005), Humana Press Inc., Totowa (NJ) 15-35
4. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006;44:209-16.
5. Wiest R., and Groszmann R.J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35 (2002) 478-491
6. Groszmann R. Hyperdynamic circulation of liver disease forty years later: pathophysiology and clinical consequences. Hepatology 20 (1994) 1359-1363
7. Moreau R., Lee S.S., Soupison T., et al. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J Hepatol 7 (1988) 98-105
8. Lebrec D., and Blanchet L. Effects of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci 68 (1985) 23-28
9. Moreau R., and Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 22 (1995) 370-376
10. Bomzon A., and Huang Y.T. Vascular smooth muscle cell signaling in cirrhosis and portal hypertension. Pharmacol Ther 89 (2001) 255-272
11. Moreau R., and Lebrec D. Molecular mechanisms of systemic vasodilation and hyperdynamic circulatory state of cirrhosis. In: Sanyal A.J., and Shah V.H. (Eds). Clinical gastroenterology: portal hypertension (2005), Humana Press Inc., Totowa (NJ) 51-64
12. Bosch J., and Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol 32 (2003) 141-156
13. Fernandez M., Vizzutti F., Garcia-Pagan J.C., et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126 (2004) 886-894
14. Fernandez M., Mejias M., Angermayr B., et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 43 (2005) 98-103
15. Pierce K.L., Premont R.T., and Lefkowitz R.J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3 (2002) 639-650
16. Clapham D.E. The G-protein nanomachine. Nature 379 (1996) 297-299
17. Somlyo A.P., and Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 372 (1994) 231-236
18. Ron D., and Kazanietz G. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13 (1999) 1658-1676
19. Ohanian V., Ohanian J., Shaw L., et al. Identification of protein kinase C isoforms in rat mesenteric small arteries and their possible role in agonist-induced contraction. Circ Res 78 (1996) 806-812
20. Moreau R. Heme oxygenase: protective enzyme or portal hypertensive molecule?. J Hepatol 34 (2001) 936-939
21. Hennenberg M., Biecker E., Trebicka J., et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology (2006) In press
22. Lincoln T.M., and Cornwell T.L. Intracellular cyclic GMP receptor proteins. FASEB J 7 (1993) 328-338
23. Tang M., Wang G., Lu P., et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9 (2003) 1506-1512
24. Tazi K.A., Moreau R., Heller J., et al. Changes in protein kinase C isoforms in association with vascular hyporeactivity in cirrhotic rat aortas. Gastroenterology 119 (2000) 201-210
25. Pateron D., Oberti F., Lefilliatre P., et al. Relationship between vascular reactivity in vitro and blood flows in rats with cirrhosis. Clin Sci 97 (1999) 313-318
26. Heller J., Schepke M., Gehnen N., et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 116 (1999) 387-393
27. Davis K.L., Martin E., Turko I.V., et al. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 41 (2001) 203-236
28. Nadaud S., Philippe M., Arnal J.F., et al. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ Res 79 (1996) 857-863
29. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
30. Pateron D., Tazi K.A., Sogni P., et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 119 (2000) 196-200
31. Tazi K.A., Barrière E., Moreau R., et al. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 122 (2002) 1869-1877
32. Wiest R., Das S., Gadelina G., et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104 (1999) 1223-1233
33. Shaul P.W. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64 (2002) 749-774
34. Fleming I., and Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol 284 (2003) R1-R12
35. Boo Y.C., and Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol 285 (2003) C499-C508
36. Nilius B., Viana F., and Droogmans G. Ion channels in vascular endothelium. Annu Rev Physiol 59 (1997) 145-170
37. + channels in in vitro NO-mediated aortic hyporeactivity to α-adrenergic vasoconstriction in rats with cirrhosis. J Hepatol 35 (2001) 350-357
38. Shah V., Wiest R., Garcia-Cardena G., et al. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 277 (1999) G463-G468
39. Tazi K.A., Moreau R., Herve P., et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 129 (2005) 303-314
40. Tsai M.H., Iwakiri Y., Cadelina G., et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 125 (2003) 1452-1461
41. Wiest R., Shah V., Sessa W.C., et al. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 276 (1999) G1043-G1051
42. Iwakiri Y., Tsai M.H., McCabe T.J., et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol 282 (2002) H2084-H2090
43. Theodorakis N.G., Wang Y.N., Skill N.J., et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 124 (2003) 1500-1508
44. Iwakiri Y., Cadelina G., Sessa W.C., et al. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol 283 (2002) G1074-G1081
45. Pilette C., Kirstetter P., Sogni P., et al. Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol 11 (1996) 1-6
46. Rabiller A., Nunes H., Lebrec D., et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 166 (2002) 514-517
47. Albillos A., de la Hera A., Gonzalez M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37 (2003) 208-217
48. Lopez-Talavera J.C., Cadelina G., Olchowski J., et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 23 (1996) 1616-1621
49. Ohta M., Tarnawski A.S., Itani R., et al. Tumor necrosis factor α regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology 27 (1998) 906-913
50. Munoz J., Albillos A., Perez-Paramo M., et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 276 (1999) G687-G693
51. Kawanaka H., Jones M.K., Szabo I.L., et al. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI3-kinase-Akt signaling pathway. Hepatology 35 (2002) 393-402
52. Lopez-Talavera J.C., Merrill W.W., et al. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 108 (1995) 761-767
53. Lopez-Talavera J.C., Levitzki A., Martinez M., et al. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 100 (1997) 664-670
54. Wiest R., Cadelina G., Milstien S., et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 38 (2003) 1508-1515
55. Xu L., Carter E.P., Ohara, et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol 279 (2000) F1110-F1115
56. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7 (2001) 827-832
57. Ros J., Claria J., To-Figueras J., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122 (2002) 85-93
58. Howlett A.C., Barth F., Bonner T.I., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
59. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
60. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
61. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676